STOCK TITAN

Oncolytics Biotech, Inc. Common Shares - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.

Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.

The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.

In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).

Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.

Rhea-AI Summary
Oncolytics Biotech® Inc. President and CEO, Dr. Matt Coffey, will join the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 15, 2024. The company will also hold virtual investor meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech Inc. announces positive 2023 data, advancements in pancreatic cancer studies, and expansion of pelareorep potential in various cancer cohorts. The company reported impressive results from the GOBLET study in anal carcinoma and plans to initiate a registration-enabling study in pancreatic cancer in 2024. The cash position of $34.9 million provides financial stability through critical milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary
Investorideas.com issues a sector snapshot on pancreatic cancer treatments, highlighting Oncolytics Biotech® Inc. The global pancreatic cancer market is projected to grow at a CAGR of 18% between 2024 and 2036, reaching a revenue of USD 36 billion by 2036.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
Rhea-AI Summary
Oncolytics Biotech Inc. announces a new Phase 1/2 cohort study evaluating pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in pancreatic cancer patients. The study, supported by a US$5 million grant from PanCAN, aims to broaden the use of pelareorep in PDAC patients. The company is optimistic about the potential of this novel treatment approach to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech Inc. to host a conference call and webcast on March 7, 2024, to discuss corporate update and financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.86%
Tags
conferences earnings
-
Rhea-AI Summary
Oncolytics Biotech® Inc. announces CEO Dr. Matt Coffey will present at Cancer Advocacy Group of Louisiana's conference. The presentation will take place on March 1, 2024, at the Ritz Carlton Hotel in New Orleans, LA. Company management will also participate in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Rhea-AI Summary
Oncolytics Biotech® Inc. expands enrollment for anal cancer cohort in GOBLET study evaluating pelareorep in combination with atezolizumab, showcasing promising clinical data exceeding success criteria. The company aims to address the unmet medical needs in advanced anal cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) announces positive Stage 1 data for pelareorep in combination with atezolizumab in anal cancer cohort of GOBLET study, showing a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response. The expansion of enrollment is supported by strong clinical data exceeding success criteria, potentially opening new treatment options for patients with advanced anal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) appoints Patricia S. Andrews to its Board of Directors, a clinical-stage immunotherapeutics company focused on oncology. Ms. Andrews brings extensive board and executive leadership experience and a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations, and business development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
management
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) reported significant 2023 accomplishments, positive clinical and translational data, and anticipated milestones for 2024. The company's cash balance of $40 million supports the initiation of the first Phase 3 study for pelareorep in pancreatic cancer, marking an important inflection point for investors and clinical collaborators. Positive results from Phase 1/2 GOBLET study and HR+/HER2- metastatic breast cancer program demonstrate the potential of pelareorep as an immunotherapeutic agent for various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none

FAQ

What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?

The current stock price of Oncolytics Biotech Common Shares (ONCY) is $0.98 as of November 21, 2024.

What is the market cap of Oncolytics Biotech Common Shares (ONCY)?

The market cap of Oncolytics Biotech Common Shares (ONCY) is approximately 75.5M.

What is Oncolytics Biotech Inc. known for?

Oncolytics Biotech Inc. is known for developing pelareorep, an innovative oncolytic virus used as a potential cancer therapeutic to enhance the immune system's response to tumors.

What cancers is Oncolytics currently targeting?

Oncolytics is targeting a variety of cancers including breast, gastrointestinal, pancreatic, and head and neck cancers through its clinical trials and research programs.

What is pelareorep?

Pelareorep is Oncolytics Biotech’s proprietary formulation of the human reovirus, designed to stimulate immune responses and make tumors more susceptible to a range of oncology treatments.

What are the recent achievements of Oncolytics Biotech?

Recent achievements include advancing to Phase III trials in head and neck cancers, receiving a US$5 million grant for pancreatic cancer research, and positive Phase 2 data in metastatic breast cancer.

How is Oncolytics Biotech funded?

Oncolytics Biotech is funded through a mix of strategic partnerships, grants, and a robust cash position to support its clinical development programs and operations.

What is the GOBLET study?

The GOBLET study is a Phase 1/2 clinical trial exploring the efficacy of pelareorep in combination with chemotherapy and checkpoint inhibitors in gastrointestinal cancers, particularly pancreatic cancer.

What are the potential benefits of pelareorep?

Pelareorep has demonstrated potential benefits such as enhancing the immune system's ability to fight cancer, increasing tumor susceptibility to treatments, and promoting an inflamed tumor phenotype.

What is the focus of Oncolytics' current clinical trials?

Oncolytics' clinical trials focus on leveraging pelareorep in combination with various chemotherapy regimens and immunotherapies to treat multiple cancer types effectively.

What partnerships does Oncolytics Biotech have?

Oncolytics partners with leading research institutions, oncology networks, and pharmaceutical companies to accelerate the development and commercialization of its therapies.

Where can I find more information about Oncolytics Biotech?

More information about Oncolytics Biotech can be found on their official website at www.oncolyticsbiotech.com or through their social media channels on LinkedIn and X (formerly Twitter).

Oncolytics Biotech, Inc. Common Shares

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

75.53M
74.22M
3.82%
1.76%
3.66%
Biotechnology
Healthcare
Link
United States of America
Calgary